PT2516406E - Agonistas de mglu2 - Google Patents

Agonistas de mglu2

Info

Publication number
PT2516406E
PT2516406E PT107984197T PT10798419T PT2516406E PT 2516406 E PT2516406 E PT 2516406E PT 107984197 T PT107984197 T PT 107984197T PT 10798419 T PT10798419 T PT 10798419T PT 2516406 E PT2516406 E PT 2516406E
Authority
PT
Portugal
Prior art keywords
mglu2 agonists
mglu2
agonists
schizophrenia
depression
Prior art date
Application number
PT107984197T
Other languages
English (en)
Portuguese (pt)
Inventor
James Allen Monn
Lourdes Prieto
Lorena Taboada Martinez
Carlos Montero Salgado
Bruce William Shaw
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2516406(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2516406E publication Critical patent/PT2516406E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT107984197T 2009-12-21 2010-12-15 Agonistas de mglu2 PT2516406E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17

Publications (1)

Publication Number Publication Date
PT2516406E true PT2516406E (pt) 2013-10-10

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107984197T PT2516406E (pt) 2009-12-21 2010-12-15 Agonistas de mglu2

Country Status (35)

Country Link
US (1) US8318184B2 (enExample)
EP (1) EP2516406B1 (enExample)
JP (1) JP5779190B2 (enExample)
KR (1) KR101395356B1 (enExample)
CN (1) CN102695701B (enExample)
AR (1) AR079343A1 (enExample)
AU (1) AU2010340039B2 (enExample)
BR (1) BR112012017188B1 (enExample)
CA (1) CA2784667C (enExample)
CR (1) CR20120322A (enExample)
CY (1) CY1114880T1 (enExample)
DK (1) DK2516406T3 (enExample)
DO (1) DOP2012000173A (enExample)
EA (1) EA020229B1 (enExample)
EC (1) ECSP12011989A (enExample)
ES (1) ES2435651T3 (enExample)
HN (1) HN2012001160A (enExample)
HR (1) HRP20131052T1 (enExample)
IL (1) IL220011A (enExample)
JO (1) JO2978B1 (enExample)
MA (1) MA33824B1 (enExample)
MX (1) MX2012007332A (enExample)
MY (1) MY160618A (enExample)
NZ (1) NZ600305A (enExample)
PE (1) PE20121688A1 (enExample)
PH (1) PH12012501253A1 (enExample)
PL (1) PL2516406T3 (enExample)
PT (1) PT2516406E (enExample)
RS (1) RS53063B (enExample)
SG (1) SG181836A1 (enExample)
SI (1) SI2516406T1 (enExample)
TN (1) TN2012000281A1 (enExample)
TW (1) TWI477490B (enExample)
UA (1) UA107684C2 (enExample)
WO (1) WO2011084437A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183304A1 (en) 2010-02-17 2012-09-27 Takeda Pharmaceutical Heterocyclic compound
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物
DK2721012T3 (en) * 2011-06-17 2016-08-15 Lilly Co Eli Biclo (3.1.0) hexane-2,6-dicarboxylic acid derivatives as MGLU2 receptor agonist
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
MX386697B (es) * 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
HUP0400620A3 (en) * 2001-01-11 2012-09-28 Lilly Co Eli Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds
US7038077B2 (en) * 2001-01-11 2006-05-02 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
KR20080058509A (ko) * 2002-06-11 2008-06-25 일라이 릴리 앤드 캄파니 흥분성 아미노산의 전구약물
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物

Also Published As

Publication number Publication date
RS53063B (sr) 2014-04-30
TWI477490B (zh) 2015-03-21
US20110152334A1 (en) 2011-06-23
US8318184B2 (en) 2012-11-27
BR112012017188A2 (pt) 2016-03-22
CA2784667A1 (en) 2011-07-14
MY160618A (en) 2017-03-15
DK2516406T3 (da) 2013-10-14
BR112012017188B1 (pt) 2021-06-22
EP2516406A1 (en) 2012-10-31
ES2435651T3 (es) 2013-12-20
ECSP12011989A (es) 2012-07-31
TN2012000281A1 (en) 2013-12-12
IL220011A0 (en) 2012-07-31
AU2010340039B2 (en) 2014-03-20
HK1171228A1 (en) 2013-03-22
CA2784667C (en) 2014-11-18
EP2516406B1 (en) 2013-09-18
TW201144290A (en) 2011-12-16
KR101395356B1 (ko) 2014-05-14
EA020229B1 (ru) 2014-09-30
UA107684C2 (xx) 2015-02-10
AR079343A1 (es) 2012-01-18
EA201290558A1 (ru) 2012-12-28
WO2011084437A1 (en) 2011-07-14
SI2516406T1 (sl) 2013-11-29
MX2012007332A (es) 2012-07-20
CN102695701B (zh) 2014-10-01
JP2013514974A (ja) 2013-05-02
NZ600305A (en) 2014-01-31
HRP20131052T1 (hr) 2013-12-06
BR112012017188A8 (pt) 2016-10-04
KR20120094056A (ko) 2012-08-23
JO2978B1 (en) 2016-03-15
MA33824B1 (fr) 2012-12-03
IL220011A (en) 2014-03-31
JP5779190B2 (ja) 2015-09-16
PH12012501253A1 (en) 2014-08-01
AU2010340039A1 (en) 2012-08-09
CN102695701A (zh) 2012-09-26
CR20120322A (es) 2012-07-10
SG181836A1 (en) 2012-08-30
DOP2012000173A (es) 2012-11-30
HN2012001160A (es) 2015-08-24
PE20121688A1 (es) 2012-12-05
CY1114880T1 (el) 2016-12-14
PL2516406T3 (pl) 2014-03-31

Similar Documents

Publication Publication Date Title
PH12012501253A1 (en) Mglu2 agonists
PH12012501355A1 (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
TN2011000673A1 (en) Bace inhibitors
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EA201171367A1 (ru) Винилиндазолильные соединения
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
PH12013500500A1 (en) Fused heteroaryls and their uses
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
CR20110361A (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapeutica como activadores de hif
EP2533796A4 (en) METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES
EA201391700A1 (ru) АГОНИСТЫ РЕЦЕПТОРА mGlu2
PH12012501547A1 (en) Methods of preparing thiazolidines
UA41660U (en) Use of jacton and mexidol as actoprotector
UA44978U (en) 2,8-dimethyl-3-dymethylaminomethylquinolione-4-on possessing anxiolytic and antiamnestic activities
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
UA41922U (ru) Применение альтана как вещества с противолучевыми свойствами
UA52379U (ru) Применение ЛИПИНА в качестве средства фригопротекторного действия
UA52376U (ru) Применение КОРВИТИНА в качестве средства фригопротекторного действия
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства
AU326123S (en) Dress
AU329266S (en) Clip
IN2013DE01110A (enExample)